Biotech Values

[DewDiligence]

(NVO)—From the same article:

…Novo still needs to get data on hypoglycemic benefits included on Tresiba’s U.S. label, something Sanofi failed to do with Toujeo. That would give the Danish company an advantage and a marketing strategy less reliant simply on price.